Risk of Hematologic Events With Coadministration of Methotrexate and the Breast Cancer Resistance Protein Inhibitor Febuxostat

Background: The breast cancer resistance protein (BCRP) is a key drug transporter found in the liver, kidney, central nervous system, and gastrointestinal tract. Due to the wide expression of BCRP, interactions of other drugs with methotrexate (MTX) may differ in oral and intravenous MTX users, and understanding of these interactions may be useful in preventing severe adverse events. Febuxostat, a urate-lowering drug, inhibits BCRP. Objective: The objective of this study was to clarify the differences in the drug-drug interaction profiles of oral and intravenous methotrexate, associated with BCRP. Methods: We analyzed the Japanese Adverse Drug Event Report database and compared the frequency of hematologic events in patients taking oral and intravenous MTX, with or without the concomitant use of febuxostat or allopurinol. Hematologic events were defined as pancytopenia and neutropenia. Multiple logistic regression analysis was then used to identify the risk factors for hematologic events in oral and intravenous MTX users. Results: We identified 8 453 oral and 810 intravenous MTX users with 546 and 126 cases of hematologic events, respectively. Compared with those not using febuxostat, a disproportionate number of hematologic events was observed in intravenous MTX users concomitantly using febuxostat (P < 0.01). The multivariate logistic analysis of intravenous MTX users showed that hematologic events were significantly associated with febuxostat use (P < 0.01) and age ≥ 60 years (P < 0.01). Conclusion and Relevance: Our findings suggest that patients being treated with intravenous MTX who concomitantly use febuxostat may be at an increased risk of hematologic events, presumably due to BCRP-mediated drug-drug interaction.

[1]  Satoru Mitsuboshi Risk of haematological events and preventive effect of folic acid in methotrexate users with chronic kidney disease and rheumatoid arthritis: Analysis of the Japanese Adverse Drug Event Report database , 2020, British journal of clinical pharmacology.

[2]  M. Kolber,et al.  Treat‐to‐Target in Gout Management? Comment on the Article by FitzGerald et al , 2020, Arthritis & rheumatology.

[3]  M. Niemi,et al.  Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin , 2020, Clinical and translational science.

[4]  G. Guyatt,et al.  2020 American College of Rheumatology Guideline for the Management of Gout , 2020, Arthritis care & research.

[5]  M. Okuda,et al.  Concomitant febuxostat enhances methotrexate-induced hepatotoxicity by inhibiting breast cancer resistance protein , 2019, Scientific Reports.

[6]  L. Hsu,et al.  Hypersensitivity and Cardiovascular Risks Related to Allopurinol and Febuxostat Therapy in Asians: A Population‐Based Cohort Study and Meta‐Analysis , 2019, Clinical pharmacology and therapeutics.

[7]  M. Melbye,et al.  Concomitant use of low‐dose methotrexate and NSAIDs and the risk of serious adverse events among patients with rheumatoid arthritis , 2018, Pharmacoepidemiology and drug safety.

[8]  D. Hira,et al.  BCRP/ABCG2 and high‐alert medications: Biochemical, pharmacokinetic, pharmacogenetic, and clinical implications , 2018, Biochemical pharmacology.

[9]  T. Buclin,et al.  Renal Drug Transporters and Drug Interactions , 2017, Clinical Pharmacokinetics.

[10]  Hirotaka Matsuo,et al.  Identification of Febuxostat as a New Strong ABCG2 Inhibitor: Potential Applications and Risks in Clinical Situations , 2016, Front. Pharmacol..

[11]  C. Pui,et al.  Preventing and Managing Toxicities of High-Dose Methotrexate , 2016, The oncologist.

[12]  K. Migita,et al.  Factors Associated with Myelosuppression Related to Low-Dose Methotrexate Therapy for Inflammatory Rheumatic Diseases , 2016, PloS one.

[13]  M. Federico,et al.  FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  S. Goodman,et al.  Outcomes related to methotrexate dose and route of administration in patients with rheumatoid arthritis: a systematic literature review. , 2015, Clinical and experimental rheumatology.

[15]  M. Joerger,et al.  Cancer chemotherapy: targeting folic acid synthesis , 2010, Cancer management and research.

[16]  B. Haraoui,et al.  Methotrexate Drug Interactions in the Treatment of Rheumatoid Arthritis: A Systematic Review , 2010, The Journal of Rheumatology.

[17]  M. Taniwaki,et al.  Statistical examination to determine whether only 48-h value for serum concentration during high-dose methotrexate therapy is a predictor for clinical adverse events using ordered logistic regression analysis , 2010, Annals of Hematology.

[18]  K. Schmiegelow Advances in individual prediction of methotrexate toxicity: a review , 2009, British journal of haematology.

[19]  A. Ilchyshyn,et al.  Methotrexate Toxicity Induced by Acute Renal Failure , 2005, Journal of the Royal Society of Medicine.

[20]  R. Fleischmann Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis , 2003, Expert opinion on drug safety.

[21]  B. Bannwarth,et al.  Clinical Pharmacokinetics of Low-Dose Pulse Methotrexate in Rheumatoid Arthritis , 1996, Clinical pharmacokinetics.

[22]  Y. Maugars,et al.  Pancytopenia and severe cytopenia induced by low-dose methotrexate. Eight case-reports and a review of one hundred cases from the literature (with twenty-four deaths) , 1995, Revue du rhumatisme.

[23]  D. Wilkinson ALLOPURINOL AND AGRANULOCYTOSIS , 1977, The Lancet.